FDA accepts Vyglxia resubmission for review, lifting Biohaven

 

• Biohaven’s October 22 8-K disclosed the FDA acceptance before 7:30 ET.
• The agency deemed the filing a complete response to November 2025’s rejection.
• FDA assigned a first-quarter 2027 goal date and plans an advisory committee.
• The resubmission included new positive supportive analyses for spinocerebellar ataxia.
• Acceptance revives a previously rejected potential commercial asset, driving the valuation reset.
• The 36.9% gain is roughly six times Biohaven’s recent average daily range.
• The fresh filing, not upcoming ESMO data, precisely matches the move’s timing.
• Review acceptance does not ensure approval; advisory committee details remain forthcoming.

https://finviz.com/stock?t=BHVN&p=d